Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia
Background There has been low community pharmacy-based naloxone supply in Australia
despite its over-the-counter status. The Behaviour Change Wheel (BCW) is a method used …
despite its over-the-counter status. The Behaviour Change Wheel (BCW) is a method used …
Opioid medicines management in primary care settings: A scoping review of quantitative studies of pharmacist activities
M Jordan, A Latif, J Mullan… - British Journal of Clinical …, 2021 - Wiley Online Library
To undertake a scoping review of pharmacist activities in opioid medicines management in
primary care settings, including those developed or led by pharmacists, or in which …
primary care settings, including those developed or led by pharmacists, or in which …
Opioid‐related policy changes: experiences and perspectives from people who use opioids to manage non‐cancer chronic pain
Introduction People who use prescription opioids to manage non‐cancer chronic pain are
particularly vulnerable to opioid‐related policy change. This study aims to better understand …
particularly vulnerable to opioid‐related policy change. This study aims to better understand …
The cost and impact of distributing naloxone to people who are prescribed opioids to prevent opioid‐related deaths: findings from a modelling study
Background and aims Although most opioid‐related mortality in Australia involves
prescription opioids, most research to understand the impact of naloxone supply on opioid …
prescription opioids, most research to understand the impact of naloxone supply on opioid …
Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study
Background In response to rising harms with prescription opioids, recent attention has
focused on how to better utilise community pharmacists to monitor outcomes with opioid …
focused on how to better utilise community pharmacists to monitor outcomes with opioid …
Overdose and take‐home naloxone in emergency settings: a pilot study examining feasibility of delivering brief interventions addressing overdose prevention with ' …
Objective Although most unintentional opioid deaths in Australia are attributed to
pharmaceutical opioids, take‐home naloxone (THN) programmes have to date …
pharmaceutical opioids, take‐home naloxone (THN) programmes have to date …
Overdose and suicide are different phenomena among opioid users that require different clinical management
Given the high rates of mental health comorbidity among opioid users, and increasing rates
of opioid prescription for chronic pain, psychiatrists and mental health clinicians are likely to …
of opioid prescription for chronic pain, psychiatrists and mental health clinicians are likely to …
[HTML][HTML] Take-home intranasal naloxone to prevent opioid overdose deaths
N Lintzeris - Medicine Today, 2020 - medicinetoday.com.au
Take-home intranasal naloxone to prevent opioid overdose deaths | Medicine Today Connect
with Sunday 16 June 2024 Home Sign up for emails Create account Subscribe Log in Home …
with Sunday 16 June 2024 Home Sign up for emails Create account Subscribe Log in Home …
Should we be routinely co‐prescribing naloxone for patients on long term opioids?
P Prathivadi, S Nielsen - The Medical Journal of Australia, 2021 - mja.com.au
Pharmaceutical Benefits Scheme (PBS) opioid prescriptions in Australia have increased
from 2.4 million in 1992 to 7 million in 2007 to 15 million prescriptions in 2016. 1 The …
from 2.4 million in 1992 to 7 million in 2007 to 15 million prescriptions in 2016. 1 The …
Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial
Background Mood, sleep and pain problems are common comorbidities among treatment-
seeking cannabis-dependent patients. There is limited evidence suggesting treatment for …
seeking cannabis-dependent patients. There is limited evidence suggesting treatment for …